[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 26 of about 26
1. Crom DB, Smith D, Xiong Z, Onar A, Hudson MM, Merchant TE, Morris EB: Health status in long-term survivors of pediatric craniopharyngiomas. J Neurosci Nurs; 2010 Dec;42(6):323-8; quiz 329-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Health status in long-term survivors of pediatric craniopharyngiomas.
  • Craniopharyngiomas are the third most common pediatric brain tumor and most common pediatric suprasellar tumor.
  • Contemporary treatment of craniopharyngiomas uses limited surgery and radiation in an effort to minimize morbidity, but the long-term health status of patients treated in this fashion has not been well described.
  • The purpose of this study was to analyze the health status of long-term survivors of pediatric craniopharyngioma treated primarily with radiation and conservative surgical resection.
  • Medical records of all long-term survivors of craniopharyngioma treated at St. Jude Children's Research Hospital and then transferred to the long-term follow-up clinic were reviewed.
  • Of these, 51 (93%) were alive at the time of this analysis.
  • At the time of analysis, the median survival was 7.6 years (range, 5.0-21.3 years).
  • Diagnosis and treatment included surgical biopsy, resection (n = 50), and radiation therapy (n=48).
  • Only 1 patient received chemotherapy.
  • In a small percentage of patients, complications may result in death even during extended remission of craniopharyngioma.
  • Because of the broad spectrum or morbidities experienced, survivors of craniopharyngioma continue to benefit from multidisciplinary care.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21207770.001).
  • [ISSN] 0888-0395
  • [Journal-full-title] The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • [ISO-abbreviation] J Neurosci Nurs
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS756555; NLM/ PMC4895693
  •  go-up   go-down


2. Bommakanti K, Panigrahi M, Yarlagadda R, Sundaram C, Uppin MS, Purohit AK: Optic chiasmatic-hypothalamic gliomas: is tissue diagnosis essential? Neurol India; 2010 Nov-Dec;58(6):833-40

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic chiasmatic-hypothalamic gliomas: is tissue diagnosis essential?
  • The advocated treatment is mainly primary radiotherapy without a histological diagnosis.
  • RESULTS: The three radiological groups were: Group-1 solid tumors with or without microcysts in 9 patients (histology: 8 pilocystic astrocytomas and 1 tuberculoma); Group-2 mixed tumors with solid and cystic components in 9 patients (histology: 7 pilocytic astrocytomas and 2 craniopharyngiomas); Group-3 ring enhancing lesions in 6 patients (all the 6 patients initially received antituberculous treatment, in 3 patients the lesion resolved and in the remaining 3 patients the lesion was subjected to biopsy as it did not resolve, the biopsy was suggestive of pilocytic astrocytoma).
  • CONCLUSIONS: Various lesions like craniopharyngiomas, tuberculomas can mimic optic chiasmatic-hypothalamic gliomas radiologically, and it is not possible to diagnose them with certainty on the basis of radiological findings alone.
  • Biopsy and tissue diagnosis should always be sought before instituting radiotherapy or chemotherapy for optic chiasmatic-hypothalamic gliomas.
  • [MeSH-minor] Adolescent. Biopsy / methods. Child. Child, Preschool. Contrast Media. Female. Humans. Magnetic Resonance Imaging / methods. Male. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurol India. 2011 Jan-Feb;59(1):144 [21339694.001]
  • (PMID = 21150045.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


3. Lehman NL: The ubiquitin proteasome system in neuropathology. Acta Neuropathol; 2009 Sep;118(3):329-47
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In neuropathology, alteration of the UPS, or mutations in UPS target proteins may result in signaling abnormalities leading to the initiation or progression of tumors such as astrocytomas, hemangioblastomas, craniopharyngiomas, pituitary adenomas, and medulloblastomas.
  • The potential for the UPS as a target of pharmacological therapy is also discussed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2007 Mar 6;104(10):4106-11 [17360485.001]
  • [Cites] Nature. 2009 May 28;459(7246):569-73 [19404257.001]
  • [Cites] Mol Cell. 2007 Apr 27;26(2):175-88 [17466621.001]
  • [Cites] Cell. 1999 Mar 5;96(5):635-44 [10089879.001]
  • [Cites] Clin Cancer Res. 2008 Sep 1;14(17):5416-25 [18765533.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] J Neurosci. 2004 Sep 29;24(39):8410-5 [15456813.001]
  • [Cites] Cell Cycle. 2006 Jul;5(14):1569-73 [16861914.001]
  • [Cites] FASEB J. 2009 Sep;23(9):2820-30 [19369384.001]
  • [Cites] Neuron. 2005 Sep 1;47(5):629-32 [16129392.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):673-82 [12209156.001]
  • [Cites] Science. 2004 Feb 13;303(5660):1026-30 [14716021.001]
  • [Cites] Curr Top Dev Biol. 2006;76:89-101 [17118264.001]
  • [Cites] J Biol Chem. 2008 Feb 8;283(6):3316-28 [18070888.001]
  • [Cites] Annu Rev Biochem. 1998;67:425-79 [9759494.001]
  • [Cites] J Biol Chem. 2000 Aug 18;275(33):25733-41 [10823831.001]
  • [Cites] Ann Neurol. 2007 May;61(5):427-34 [17469116.001]
  • [Cites] Blood. 2007 Nov 15;110(10):3557-60 [17690257.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12876-82 [14709552.001]
  • [Cites] J Biol Chem. 1992 Dec 5;267(34):24315-21 [1447181.001]
  • [Cites] Neurochem Int. 2007 Jul-Sep;51(2-4):105-11 [17586089.001]
  • [Cites] Cell Div. 2008 Apr 22;3:8 [18430235.001]
  • [Cites] J Clin Invest. 2007 Dec;117(12):3940-51 [17992259.001]
  • [Cites] Neuron. 2003 Mar 6;37(5):735-49 [12628165.001]
  • [Cites] Curr Biol. 1999 Feb 25;9(4):207-10 [10074433.001]
  • [Cites] J Neurochem. 2008 Dec;107(6):1471-81 [19094054.001]
  • [Cites] Toxicol Pathol. 2008 Feb;36(2):345-52 [18362199.001]
  • [Cites] J Biol Chem. 2000 Mar 24;275(12):8929-35 [10722740.001]
  • [Cites] Cell Signal. 2008 Oct;20(10):1725-39 [18602463.001]
  • [Cites] Acta Neuropathol. 2000 Jul;100(1):43-9 [10912919.001]
  • [Cites] Oncogene. 2004 Mar 25;23(13):2408-19 [14743209.001]
  • [Cites] J Child Neurol. 2008 Aug;23(8):912-5 [18487518.001]
  • [Cites] J Biol Chem. 2003 Jun 13;278(24):21323-6 [12719435.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Apr 1;166(1):74-81 [16616114.001]
  • [Cites] Nat Neurosci. 2009 Jun;12(6):777-83 [19430469.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):5484-9 [11729185.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2009;49:73-96 [18834306.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2008 Oct;79(10):1186-9 [18796596.001]
  • [Cites] J Biol Chem. 2004 Oct 1;279(40):42290-301 [15280365.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2007 Jun;78(6):626-8 [17210620.001]
  • [Cites] Mol Cancer Res. 2006 Oct;4(10):695-707 [17050664.001]
  • [Cites] Hum Mol Genet. 2008 Dec 15;17(24):3942-52 [18784277.001]
  • [Cites] PLoS One. 2009;4(3):e4973 [19319192.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] J Cell Sci. 2004 Jan 15;117(Pt 2):281-92 [14657277.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2629-34 [19196987.001]
  • [Cites] Neurobiol Dis. 2005 Dec;20(3):646-55 [15936949.001]
  • [Cites] Trends Cell Biol. 2000 Dec;10(12):524-30 [11121744.001]
  • [Cites] J Cell Biol. 2008 Mar 24;180(6):1177-89 [18362179.001]
  • [Cites] Oncogene. 2008 Oct 9;27(46):6002-11 [18574468.001]
  • [Cites] J Neurochem. 2005 Mar;92(6):1531-41 [15748170.001]
  • [Cites] J Mol Biol. 2006 Mar 3;356(4):1027-35 [16405905.001]
  • [Cites] Cell Mol Life Sci. 2007 Mar;64(5):601-9 [17256086.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):159-67 [18553091.001]
  • [Cites] Cancer Res. 2009 Mar 15;69(6):2314-23 [19276349.001]
  • [Cites] Neurology. 2006 Sep 26;67(6):1074-7 [16807408.001]
  • [Cites] J Biol Chem. 2009 Feb 20;284(8):5030-41 [19098288.001]
  • [Cites] Neurosci Lett. 2008 Jan 31;431(2):141-5 [18191026.001]
  • [Cites] Cell. 2001 Jun 1;105(5):645-55 [11389834.001]
  • [Cites] Hum Mutat. 2000 Jul;16(1):89-90 [10874314.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2008 May;16(3):274-8 [18301241.001]
  • [Cites] Mol Biol Cell. 2003 Jul;14(7):2809-17 [12857866.001]
  • [Cites] EMBO J. 2009 Feb 18;28(4):372-82 [19153604.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Feb;66(2):152-7 [17279000.001]
  • [Cites] Arch Neurol. 2008 Aug;65(8):1031-8 [18695053.001]
  • [Cites] FASEB J. 2008 Nov;22(11):3785-94 [18632848.001]
  • [Cites] Hum Mol Genet. 2008 Mar 15;17(6):906-17 [18065497.001]
  • [Cites] Am J Pathol. 2007 May;170(5):1793-805 [17456782.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5500-5 [15064394.001]
  • [Cites] J Neurosci. 2008 Dec 3;28(49):13285-95 [19052220.001]
  • [Cites] Genes Dev. 2006 Sep 1;20(17):2410-20 [16921029.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000382 [19214209.001]
  • [Cites] Hum Mol Genet. 2001 May 15;10(11):1201-13 [11371513.001]
  • [Cites] Cancer Res. 2008 Dec 15;68(24):10094-104 [19074875.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2439-44 [10051661.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38851-61 [16157591.001]
  • [Cites] Mol Cell Biol. 2007 Nov;27(22):7955-65 [17875940.001]
  • [Cites] J Alzheimers Dis. 2009;17(2):319-25 [19363271.001]
  • [Cites] J Biol Chem. 2009 Apr 10;284(15):9796-803 [19218238.001]
  • [Cites] Oncogene. 2006 Jan 5;25(1):1-7 [16278683.001]
  • [Cites] Hum Mol Genet. 2009 Apr 15;18(8):1384-94 [19168853.001]
  • [Cites] Hum Mol Genet. 2008 Oct 15;17(20):3223-35 [18658163.001]
  • [Cites] Trends Cell Biol. 2002 May;12(5):216-21 [12062168.001]
  • [Cites] Nature. 2005 Nov 10;438(7065):224-8 [16227972.001]
  • [Cites] Neurobiol Dis. 2009 Jul;35(1):32-41 [19348945.001]
  • [Cites] Nat Struct Mol Biol. 2008 Dec;15(12):1334-42 [19043414.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):142-8 [10663629.001]
  • [Cites] Biochem Biophys Res Commun. 2009 Jun 5;383(3):331-5 [19358826.001]
  • [Cites] Cell Signal. 2007 Mar;19(3):573-81 [17005371.001]
  • [Cites] Biochem J. 2009 Mar 15;418(3):643-50 [19049493.001]
  • [Cites] J Exp Med. 1996 Apr 1;183(4):1545-52 [8666912.001]
  • [Cites] Eur J Neurol. 2008 Aug;15(8):772-80 [18684309.001]
  • [Cites] Methods Enzymol. 2005;399:334-55 [16338367.001]
  • [Cites] Mol Cell. 2009 May 15;34(3):259-69 [19450525.001]
  • [Cites] Acta Neuropathol. 2008 Aug;116(2):147-57 [18536926.001]
  • [Cites] Drug News Perspect. 2007 Jul-Aug;20(6):365-70 [17925890.001]
  • [Cites] PLoS Genet. 2009 Feb;5(2):e1000383 [19214206.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3103-11 [15126347.001]
  • [Cites] J Neurochem. 2008 Jul;106(1):107-20 [18346206.001]
  • [Cites] Autophagy. 2008 Apr;4(3):372-4 [18216494.001]
  • [Cites] Biochemistry. 2007 Dec 25;46(51):14889-98 [18044963.001]
  • [Cites] J Pathol. 2003 Feb;199(2):259-66 [12533840.001]
  • [Cites] J Biol Chem. 1996 May 10;271(19):11339-46 [8626687.001]
  • [Cites] Neuron. 2003 Jul 17;39(2):217-25 [12873380.001]
  • [Cites] J Neurochem. 2004 Jul;90(2):379-91 [15228595.001]
  • [Cites] J Neuropathol Exp Neurol. 2007 Oct;66(10):884-91 [17917582.001]
  • [Cites] Mod Pathol. 2000 Apr;13(4):420-6 [10786809.001]
  • [Cites] Science. 2002 Jul 19;297(5580):365-9 [12130776.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):358-66 [11988738.001]
  • [Cites] Hum Mol Genet. 2005 Apr 15;14(8):1049-58 [15757975.001]
  • [Cites] J Biol Chem. 2009 Jan 30;284(5):3250-63 [19033443.001]
  • [Cites] Mol Cell Biol. 2005 Apr;25(7):2795-807 [15767683.001]
  • [Cites] FEBS J. 2009 Mar;276(5):1208-20 [19175675.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15690-5 [18836078.001]
  • [Cites] ScientificWorldJournal. 2008;8:421-33 [18454252.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):639-46 [18936941.001]
  • [Cites] J Biol Chem. 1982 Mar 10;257(5):2543-8 [6277905.001]
  • [Cites] J Biol Chem. 2002 Aug 9;277(32):28530-6 [12032152.001]
  • [Cites] Nature. 2004 Oct 14;431(7010):805-10 [15483602.001]
  • [Cites] Exp Neurol. 2007 Feb;203(2):531-41 [17097639.001]
  • [Cites] EMBO J. 1998 Jan 2;17(1):61-70 [9427741.001]
  • [Cites] Nat Rev Cancer. 2006 Mar;6(3):184-92 [16453012.001]
  • [Cites] Dev Cell. 2003 Jun;4(6):799-812 [12791266.001]
  • [Cites] J Biol Chem. 2005 Sep 9;280(36):32026-34 [16040601.001]
  • [Cites] Proc Natl Acad Sci U S A. 2009 Feb 24;106(8):2897-902 [19196961.001]
  • [Cites] Eur J Neurosci. 2008 Nov;28(10):1980-8 [19046380.001]
  • [Cites] Mol Cell Proteomics. 2008 Nov;7(11):2107-22 [18565875.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4606-18 [16914519.001]
  • [Cites] Cell. 2009 May 15;137(4):609-22 [19450511.001]
  • [Cites] J Immunol. 1995 Oct 15;155(8):3750-8 [7561079.001]
  • [Cites] Nature. 2007 Aug 9;448(7154):704-8 [17687326.001]
  • [Cites] Science. 2001 Oct 5;294(5540):173-7 [11533444.001]
  • [Cites] Mol Cell Neurosci. 2002 Jun;20(2):298-306 [12093161.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17):5275-87 [18573876.001]
  • [Cites] J Cell Biol. 2003 Oct 13;163(1):27-33 [14557245.001]
  • [Cites] Neuron. 2004 Nov 18;44(4):601-7 [15541309.001]
  • [Cites] J Neurosci. 2008 Jul 2;28(27):6926-37 [18596167.001]
  • [Cites] Genes Dev. 2006 Sep 15;20(18):2539-51 [16980583.001]
  • [Cites] J Clin Invest. 2009 Mar;119(3):650-60 [19229105.001]
  • [Cites] Mol Biol Cell. 2007 Apr;18(4):1129-42 [17229889.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):16041-6 [14668431.001]
  • [Cites] J Biol Chem. 2009 Mar 20;284(12):8083-92 [19112176.001]
  • [Cites] Mol Cancer Ther. 2009 Apr;8(4):930-9 [19372566.001]
  • [Cites] Acta Neuropathol. 2008 Dec;116(6):625-37 [18843496.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5906-11 [12384556.001]
  • [Cites] Nat Rev Neurosci. 2008 Nov;9(11):826-38 [18931696.001]
  • [Cites] Annu Rev Immunol. 2004;22:81-127 [15032575.001]
  • [Cites] J Biol Chem. 2008 Mar 21;283(12):7648-56 [18201976.001]
  • (PMID = 19597829.001).
  • [ISSN] 1432-0533
  • [Journal-full-title] Acta neuropathologica
  • [ISO-abbreviation] Acta Neuropathol.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / K08 NS045077
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Ubiquitin; EC 3.4.25.1 / Proteasome Endopeptidase Complex
  • [Number-of-references] 149
  • [Other-IDs] NLM/ PMC2716447
  •  go-up   go-down


Advertisement
4. Ierardi DF, Fernandes MJ, Silva IR, Thomazini-Gouveia J, Silva NS, Dastoli P, Toledo SR, Cavalheiro S: Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas. Childs Nerv Syst; 2007 Sep;23(9):1041-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis in alpha interferon (IFN-alpha) intratumoral chemotherapy for cystic craniopharyngiomas.
  • OBJECTIVES: The aim of this study was to verify whether intracystic injections of alpha-Interferon (IFN-alpha) in cystic craniopharyngiomas were able to reduce the tumor by activating the Fas apoptotic pathway.
  • MATERIALS AND METHODS: Twenty-one patients with cystic craniopharyngiomas treated at the Pediatric Oncology Institute (IOP/GRAACC) of Federal University of São Paulo were submitted to intracystic chemotherapy with IFN-alpha.
  • CONCLUSIONS: Our data demonstrated that the IFN-alpha was able to induce Fas-mediated apoptosis together with a reduction in the tumor size; such an observation may suggest the importance to investigate still unexplored mechanisms to be exploited in craniopharyngioma therapy.
  • [MeSH-major] Apoptosis / drug effects. Craniopharyngioma / therapy. Drug Therapy / methods. Immunologic Factors / therapeutic use. Interferon-alpha / therapeutic use. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Enzyme-Linked Immunosorbent Assay / methods. Fas Ligand Protein / metabolism. Female. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Retrospective Studies. Tomography Scanners, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Medicines and Children.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):719-24 [16133276.001]
  • [Cites] Pituitary. 2006;9(4):323-6 [17080265.001]
  • [Cites] Acta Oncol. 1998;37(4):331-8 [9743454.001]
  • [Cites] J Neurosurg. 2000 Feb;92 (2):255-60 [10659012.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1205-13 [9547332.001]
  • [Cites] Adv Pediatr. 2006;53:183-209 [17089867.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):213-6; discussion 216-7 [10626953.001]
  • [Cites] J Neurosurg. 1980 May;52(5):661-6 [7373393.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):124-6 [8613819.001]
  • [Cites] Expert Rev Mol Med. 2001 Dec 10;2001:1-18 [14987370.001]
  • [Cites] Childs Nerv Syst. 2001 Dec;17 (12 ):724-30 [11862438.001]
  • [Cites] No Shinkei Geka. 1974 Oct;2(10 ):683-8 [4140477.001]
  • [Cites] Clin Neuropathol. 2003 Sep-Oct;22(5):229-34 [14531547.001]
  • [Cites] J Exp Med. 1997 Dec 15;186(12):2045-50 [9396774.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):701-4 [15928963.001]
  • [Cites] Brain Res Brain Res Rev. 2004 Jan;44(1):65-81 [14739003.001]
  • [Cites] J Neurosurg. 2004 Aug;101(1 Suppl):85-90 [16206977.001]
  • (PMID = 17593372.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fas Ligand Protein; 0 / Immunologic Factors; 0 / Interferon-alpha
  •  go-up   go-down


5. Mottolese C, Szathmari A, Berlier P, Hermier M: Craniopharyngiomas: our experience in Lyon. Childs Nerv Syst; 2005 Aug;21(8-9):790-8
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngiomas: our experience in Lyon.
  • OBJECTIVE: We reviewed our experience in surgical treatment of craniopharyngiomas.
  • Surgical treatment of craniopharyngiomas in children represents a challenge for neurosurgeons because it presents a different set of surgical problems.
  • Two groups of patients were distinguished: a group of 36 patients treated with surgical direct surgery; a second group of 24 patients treated only with intracystic chemotherapy with bleomycin (18 patients) or associated with surgery (six patients).
  • All patients presented ante-pituitary insufficiency and diabetes insipidus, which required substitutive treatment.
  • In the group treated with bleomycin, 18 patients presented a primary cystic or a mixed form of craniopharyngioma and six patients showed a cystic recurrence.
  • CONCLUSION: Our experience showed that in the group treated with intracystic chemotherapy alone, results were better with a low rate of morbidity and mortality.
  • In cases of cystic craniopharyngiomas, we considered bleomycin as the treatment of choice.
  • For solid forms or for cases resistant to intracystic chemotherapy with bleomycin, direct surgery has to be proposed.
  • [MeSH-major] Craniopharyngioma / surgery. Cysts / surgery. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. France. Humans. Infant. Magnetic Resonance Imaging. Male. Neurosurgical Procedures. Radiosurgery. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1982 Sep;11(3):382-9 [7133354.001]
  • [Cites] Acta Neurochir (Wien). 1989;99(1-2):11-9 [2667282.001]
  • [Cites] Radiother Oncol. 1993 Apr;27(1):13-21 [8327728.001]
  • [Cites] Clin Neurosurg. 1980;27:188-205 [7273553.001]
  • [Cites] Surg Neurol. 1978 Jan;9(1):11-4 [622676.001]
  • [Cites] J Neurosurg. 1972 Mar;36(3):299-302 [5059968.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):3-11 [2352020.001]
  • [Cites] J Neurosurg. 1977 Aug;47(2):218-27 [874545.001]
  • [Cites] Childs Brain. 1979;5(5):433-49 [477460.001]
  • [Cites] Neurochirurgie. 1997;43(4):187-210; discussion 211 [9686222.001]
  • [Cites] Neurosurgery. 1995 Apr;36(4):715-24 [7596502.001]
  • [Cites] Psychoneuroendocrinology. 1977 Oct;2(4):365-72 [601173.001]
  • [Cites] Childs Brain. 1980;6(2):57-64 [7353444.001]
  • [Cites] Acta Neurochir Suppl (Wien). 1985;35:94-100 [3867266.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):1-10 [8438080.001]
  • [Cites] Surg Neurol. 1973 Jan;1(1):5-12 [4544703.001]
  • [Cites] Neurosurgery. 1989 Jan;24(1):53-9 [2927598.001]
  • [Cites] Clin Neurosurg. 1986;33:533-46 [3791815.001]
  • [Cites] Childs Brain. 1982;9(3-4):179-87 [7049599.001]
  • [Cites] J Neurosurg. 2005 Apr;102(4):650-7 [15871507.001]
  • [Cites] J Neurosurg. 1985 Apr;62(4):496-501 [3973718.001]
  • [Cites] Br J Neurosurg. 1992;6(3):187-93 [1632917.001]
  • [Cites] Pediatr Neurosurg. 2000 Oct;33(4):211-8 [11124639.001]
  • [Cites] Clin Neurosurg. 1976;23:52-79 [975700.001]
  • [Cites] J Neurosurg. 1969 Apr;30(4):377-90 [4308176.001]
  • [Cites] J Neurosurg. 1983 Sep;59(3):409-17 [6886754.001]
  • [Cites] J Neurosurg. 1985 Feb;62(2):174-81 [3968556.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1053-7; discussion 1057-8 [11846897.001]
  • [Cites] J Neurosurg Sci. 1989 Jan-Mar;33(1):145-8 [2476533.001]
  • [Cites] Childs Nerv Syst. 2001 Dec;17 (12 ):724-30 [11862438.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):502-12 [2204689.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Neurosurgery. 2004 Apr;54(4):813-20; discussion 820-2 [15046646.001]
  • [Cites] Prog Exp Tumor Res. 1987;30:350-8 [3628817.001]
  • [Cites] Pediatr Neurosurg. 1993;19(1):6-14 [8422329.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):291-302; discussion 302-5 [10690718.001]
  • [Cites] Neurosurgery. 2000 Oct;47(4):857-63; discussion 863-5 [11014425.001]
  • (PMID = 15971075.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


6. Ohmori K, Collins J, Fukushima T: Craniopharyngiomas in children. Pediatr Neurosurg; 2007;43(4):265-78
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngiomas in children.
  • BACKGROUND: The modern era of pediatric craniopharyngioma treatment includes multiple modalities including microsurgical resection, irradiation, brachytherapy or chemotherapy.
  • No clear consensus as to the best therapeutic approach has yet been established.
  • The aim of this study was to describe the techniques and strategies for the treatment of pediatric craniopharyngiomas in light of a literature review with particular attention to the incidence of adverse postoperative effects.
  • METHODS: Twenty-seven pediatric patients (median age 9.0 years) who were surgically treated for craniopharyngiomas were evaluated.
  • We reviewed the recent literature for clinical features of craniopharyngiomas in children, including the present cases.
  • According to the literature, recurrence rates range from zero to 52.8% (average 16.1%) in the gross total resection group, 51.1% in the subtotal resection without radiation therapy group, and 33.5% in the subtotal resection with radiation therapy group.
  • CONCLUSIONS: For patients in whom early postoperative MRI reveals complete craniopharyngioma removal, a very low rate of recurrence is anticipated.
  • In the authors' experience, radiographically total excision of even large craniopharyngiomas can be safely achieved by one or a combination of several advanced microsurgical techniques, sometimes by a staged strategy.
  • [MeSH-major] Craniopharyngioma / surgery. Neurosurgical Procedures / methods. Pituitary Neoplasms / surgery
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cohort Studies. Female. Humans. Male. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 S. Karger AG, Basel.
  • (PMID = 17627142.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 61
  •  go-up   go-down


7. Park DH, Park JY, Kim JH, Chung YG, Lee HK, Lee KC, Suh JK: Outcome of postoperative intratumoral bleomycin injection for cystic craniopharyngioma. J Korean Med Sci; 2002 Apr;17(2):254-9
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of postoperative intratumoral bleomycin injection for cystic craniopharyngioma.
  • Total excision is a treatment of choice in preventing the relapse of craniopharyngioma, but for tumors involving an extensive area, it is often associated with an increased risk of complications.
  • We have performed a partial or subtotal tumor removal followed by repeated injection of bleomycin into the remaining tumor through a subcutaneous reservoir as postoperative adjuvant therapy.
  • A retrospective review of clinical, radiological, and surgical data was performed for 10 patients (5 males and 5 females; age, 3-65 yr; follow-up duration, 12-79 months) with cystic craniopharyngiomas.
  • Our study demonstrates that postoperative bleo-mycin injection for cystic craniopharyngioma, although does not appear to eradicate the tumor, decreases and stabilizes the tumor size, when used as an adjuvant therapy in young patients.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy. Postoperative Care
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / radiation effects. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Injections. L-Lactate Dehydrogenase / metabolism. Male. Middle Aged. Retrospective Studies. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11961313.001).
  • [ISSN] 1011-8934
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Other-IDs] NLM/ PMC3054855
  •  go-up   go-down


8. Mottolese C, Stan H, Hermier M, Berlier P, Convert J, Frappaz D, Lapras C: Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas. Childs Nerv Syst; 2001 Dec;17(12):724-30
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intracystic chemotherapy with bleomycin in the treatment of craniopharyngiomas.
  • OBJECT: Since bleomycin has not yet been used very frequently in the treatment of patients with craniopharyngioma, it seemed important to document the course of a series of such patients treated with this preparation.
  • METHODS AND RESULTS: Local chemotherapy with bleomycin was performed in 24 patients (20 children and 4 adults), 16 of whom presented with cystic or mixed (solid/cystic) craniopharyngioma and 8, with recurrent cystic craniopharyngioma.
  • The drug was administered through an Ommaya reservoir, which was placed either by using a direct surgical approach (6 patients) or a stereotactic approach (16 patients), or with endoscopic assistance in patients with hydrocephaly (2 patients).
  • Most patients (17, or 70%) were treated only with intracystic chemotherapy.
  • Chemotherapy was followed by surgery in 7 patients.
  • Five were operated on at the beginning of our study, and 2 required surgery because chemotherapy yielded poor results.
  • CONCLUSION: Our results show that bleomycin can be an alternative in the treatment of cystic craniopharyngiomas or cystic recurrences, as it reduces surgical morbidity and improves clinical results.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Administration Routes. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infant. Male. Middle Aged. Neoplasm Recurrence, Local. Retrospective Studies. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11862438.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


9. Jiang R, Liu Z, Zhu C: Preliminary exploration of the clinical effect of bleomycin on craniopharyngiomas. Stereotact Funct Neurosurg; 2002;78(2):84-94
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary exploration of the clinical effect of bleomycin on craniopharyngiomas.
  • OBJECTIVE: To investigate the antitumor effect of bleomycin on craniopharyngiomas.
  • METHODS: A series of cystic craniopharyngiomas were randomly divided into three groups: (A) intracystic chemotherapy with bleomycin;.
  • Outcome was based on a comparison of the volume of cysts before treatment and at follow-up.
  • The index and lactate dehydrogenase (LD) of the cystic fluids, blood and cerebrospinal fluids and the endocrine function of these patients were determined before and after therapy.
  • RESULTS: 19 patients finished the whole therapeutic course: 5 from group A, 9 from group B and 5 from group C.
  • Four tumors in group A were polycystic, and the drug was selectively injected into the largest cyst.
  • At follow-up, the volumes of the cysts in groups A and B regressed from 92 to 0%, while the drug-free cysts enlarged.
  • CONCLUSION: Bleomycin injected into cysts of craniopharyngiomas causes the tumor to shrink.
  • When (32)P is added, the therapeutic effect seems better than treatment with either (32)P or bleomycin alone.
  • Blood chemistry, liver, kidney and endocrine functions change little irrespective of the therapy applied.
  • However, the combination of chemotherapy and radiotherapy may severely disturb both serum electrolytes and endocrine function.
  • LD and its isoenzymes in the cystic fluids, CSF and serum may not change after bleomycin treatment.
  • [MeSH-major] Bleomycin / therapeutic use. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Chi-Square Distribution. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neuronavigation / statistics & numerical data. Phosphorus Radioisotopes / therapeutic use. Radiosurgery / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 S. Karger AG, Basel
  • (PMID = 12566834.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Phosphorus Radioisotopes; 11056-06-7 / Bleomycin
  •  go-up   go-down


10. Cavalheiro S, Di Rocco C, Valenzuela S, Dastoli PA, Tamburrini G, Massimi L, Nicacio JM, Faquini IV, Ierardi DF, Silva NS, Pettorini BL, Toledo SR: Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases. Neurosurg Focus; 2010 Apr;28(4):E12
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Craniopharyngiomas: intratumoral chemotherapy with interferon-alpha: a multicenter preliminary study with 60 cases.
  • OBJECT: The authors assessed the efficacy of intratumoral interferon-alpha (IFNalpha)-based chemotherapy in pediatric patients with cystic craniopharyngiomas.
  • METHODS: In a prospective multicenter study of 60 pediatric patients, the authors assessed the efficacy of intratumoral INFalpha2A-based chemotherapy.
  • RESULTS: Sixty cases of cystic craniopharyngioma were analyzed.
  • CONCLUSIONS: This has been the largest documented series of intratumoral chemotherapy using INFalpha for the control of cystic craniopharyngiomas.
  • The treatment has proved efficacious; there was no mortality, and morbidity rates were low.
  • [MeSH-major] Craniopharyngioma / drug therapy. Interferon-alpha / administration & dosage. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Child. Child, Preschool. Cohort Studies. Drug Administration Schedule. Female. Humans. Infant. Injections, Intralesional. Magnetic Resonance Imaging. Male. Neuronavigation. Prospective Studies. Treatment Outcome. Tumor Burden

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20367356.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha
  •  go-up   go-down


11. Jakacki RI, Cohen BH, Jamison C, Mathews VP, Arenson E, Longee DC, Hilden J, Cornelius A, Needle M, Heilman D, Boaz JC, Luerssen TG: Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas. J Neurosurg; 2000 Feb;92(2):255-60
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II evaluation of interferon-alpha-2a for progressive or recurrent craniopharyngiomas.
  • OBJECT: Craniopharyngiomas originate from the same cells as squamous cell skin carcinoma, which can be treated successfully with interferon-alpha (IFNalpha)-2a.
  • The authors evaluated the activity and toxicity of systemic IFN in young patients with craniopharyngiomas.
  • METHODS: Fifteen patients between the ages of 4.2 and 19.8 years who had progressive or recurrent craniopharyngiomas were enrolled in this study.
  • Nine of these patients had never received external-beam radiation therapy.
  • Therapy consisted of 8,000,000 U/m2 IFNalpha-2a administered daily for 16 weeks (induction phase) followed by the same dose three times per week for an additional 32 weeks (maintenance phase).
  • Of the 12 patients who could be evaluated, radiological studies demonstrated a response to treatment in three with predominantly cystic tumors (one minor response, one partial response, and one complete response); one of these patients also showed improvement in visual fields.
  • The size of the cystic component of the tumors often increased temporarily during the first several months of therapy.
  • Three patients met the criteria for progressive disease during therapy.
  • The median time to progression was 25 months.
  • The need for radiation therapy in patients treated with IFN was delayed for 18 to 35 months (median 25 months) in six patients.
  • All patients developed transient flulike symptoms shortly after receiving the first dose of IFN.
  • Other toxicities (predominantly hepatic, neurological, and cutaneous) were seen in nine (60%) of the 15 patients during the first 8 weeks of treatment but resolved after temporary discontinuation and/or dose reduction.
  • CONCLUSIONS: Interferon-alpha-2a is active against some childhood craniopharyngiomas; its toxicity precludes administration of high daily doses, and the optimum dose level and schedule remain to be defined.
  • [MeSH-major] Craniopharyngioma / drug therapy. Interferon-alpha / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Disease Progression. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Humans. Injections, Subcutaneous. Magnetic Resonance Imaging. Male. Pituitary Gland / pathology. Radiotherapy, Adjuvant. Recombinant Proteins. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10659012.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


12. Hader WJ, Steinbok P, Hukin J, Fryer C: Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children. Pediatr Neurosurg; 2000 Oct;33(4):211-8
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intratumoral therapy with bleomycin for cystic craniopharyngiomas in children.
  • Surgical removal of cystic craniopharyngiomas in children is associated with significant operative morbidity and recurrence rates.
  • The purpose of this study was to review our experience with a less invasive therapy, namely, intratumoral bleomycin, in the treatment of predominantly cystic craniopharyngiomas.
  • All children with craniopharyngiomas treated at a tertiary care pediatric neurosurgical center since 1994, when bleomycin was first used, were reviewed retrospectively.
  • Seven patients received intratumoral bleomycin therapy.
  • Patients received 2-5 mg bleomycin per dose, 3 times per week, for 3-5 weeks as an initial course.
  • In 4 patients, treatment resulted in a significant decrease (>50%) in tumor size, which has remained stable.
  • One patient developed peritumoral edema as a result of bleomycin therapy.
  • Intratumoral bleomycin is a useful alternative therapy for cystic craniopharyngiomas, and may control tumor growth and delay potentially harmful resection and/or radiotherapy in young children.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Bleomycin / administration & dosage. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Brain Edema. Child, Preschool. Cysts / drug therapy. Dose-Response Relationship, Drug. Female. Humans. Infant. Injections, Intralesional. Male. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 S. Karger AG, Basel
  • (PMID = 11124639.001).
  • [ISSN] 1016-2291
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


13. Cannavò S, Marini F, Trimarchi F: Patients with craniopharyngiomas: therapeutical difficulties with growth hormone. J Endocrinol Invest; 2008 Sep;31(9 Suppl):56-60
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with craniopharyngiomas: therapeutical difficulties with growth hormone.
  • Craniopharyngioma (CP) is a rare and benign tumor of the pituitary region.
  • The risk of CP recurrence or progression due to rGH therapy is unproven.
  • Treatment with rGH improves significantly the quality of life (QoL), although body composition and lipid abnormalities are not modified.
  • During 3-yr rGH treatment mean body mass index, fat mass percentage, and both hip and waist circumferences decreased significantly only in CO patients.
  • [MeSH-major] Craniopharyngioma / drug therapy. Human Growth Hormone / adverse effects. Human Growth Hormone / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Aged. Body Mass Index. Child. Databases, Factual. Hormone Replacement Therapy / adverse effects. Humans. Hypopituitarism / drug therapy. Hypopituitarism / epidemiology. Hypopituitarism / etiology. Hypopituitarism / psychology. Middle Aged. Prevalence. Quality of Life

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020388.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 12629-01-5 / Human Growth Hormone
  •  go-up   go-down


14. Pettorini BL, Inzitari R, Massimi L, Tamburrini G, Caldarelli M, Fanali C, Cabras T, Messana I, Castagnola M, Di Rocco C: The role of inflammation in the genesis of the cystic component of craniopharyngiomas. Childs Nerv Syst; 2010 Dec;26(12):1779-84
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of inflammation in the genesis of the cystic component of craniopharyngiomas.
  • BACKGROUND: Craniopharyngioma accounts for 5-10% of childhood tumors and, despite of the benign histological features, its clinical course can be malignant because of critical anatomical relationships with neural and vascular structures and the possible morbidity associated to resection.
  • METHODS: The acidic soluble proteins contained in the cystic fluid of six patients with cystic craniopharyngioma, three of them treated with intratumoral interferon-α, were analyzed.
  • FINDINGS: The antimicrobial peptides α-defensins 1-3 relevant for innate immunity were detected in the cystic fluid before the intratumoral treatment.
  • Amount of peptides significantly decreased in cystic fluid during pharmacological treatment.
  • INTERPRETATION: Detection of α-defensins 1-3 excludes that cyst fluid formation can derive from disruption of blood-brain barrier and suggests the involvement of innate immune response in pathology of craniopharyngioma cyst formation.
  • The reduction of α-defensins could derive both from direct antitumoral effect of interferon-α on squamous epithelial cells of craniopharyngioma cyst and from its immuno-modulatory effects on the recruitment of cells of innate immune systems.
  • Additional studies will be necessary to establish the role of these molecules in the pathogenesis of craniopharyngioma, and further investigations will be necessary to confirm the efficacy of the antitumoral activity of interferon-α.
  • [MeSH-major] Craniopharyngioma / immunology. Cysts / immunology. Inflammation / immunology. Pituitary Neoplasms / immunology
  • [MeSH-minor] Child. Child, Preschool. Chromatography, High Pressure Liquid. Cyst Fluid / chemistry. Cyst Fluid / immunology. Female. Humans. Immunity, Innate / immunology. Immunologic Factors / administration & dosage. Injections, Intraventricular. Interferon-alpha / administration & dosage. Male. Spectrometry, Mass, Electrospray Ionization. alpha-Defensins / analysis. alpha-Defensins / immunology. alpha-Defensins / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):719-24 [16133276.001]
  • [Cites] J Neurosurg. 1999 Nov;91(5):831-4 [10541241.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Jul;90(1):78-81 [10884640.001]
  • [Cites] Surg Neurol. 1993 Nov;40(5):414-9 [8211660.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5551-8 [9850093.001]
  • [Cites] Med Pediatr Oncol. 2003 Apr;40(4):214-8 [12555247.001]
  • [Cites] Eur J Haematol. 1990 Jan;44(1):1-8 [2407547.001]
  • [Cites] Neurosurgery. 1997 Dec;41(6):1359-63; discussion 1363-4 [9402587.001]
  • [Cites] Surg Neurol. 1991 Oct;36(4):286-93 [1948629.001]
  • [Cites] J Anat. 1991 Oct;178:133-44 [1810922.001]
  • [Cites] Acta Pathol Jpn. 1985 Mar;35(2):339-50 [3895822.001]
  • [Cites] Childs Nerv Syst. 2007 Sep;23(9):1041-6 [17593372.001]
  • [Cites] Adv Cancer Res. 1986;46:1-265 [2425561.001]
  • [Cites] J Lab Clin Med. 1993 Aug;122(2):202-7 [8340706.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jun;144(6):551-4; discussion 554 [12111487.001]
  • [Cites] J Am Soc Mass Spectrom. 1998 Mar;9(3):225-33 [9879360.001]
  • [Cites] Eur J Oral Sci. 2005 Dec;113(6):462-8 [16324135.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Neurocirugia (Astur). 2002 Dec;13(6):479-85; discussion 485 [12529778.001]
  • [Cites] Pharmacol Ther. 1995 May;66(2):191-205 [7667395.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):738-43 [3338036.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):738-45 [11857307.001]
  • [Cites] Neurol Res. 1999 Dec;21(8):796-8 [10596392.001]
  • [Cites] Biochimie. 2007 Jun-Jul;89(6-7):884-93 [17532550.001]
  • [Cites] Childs Nerv Syst. 2005 Aug;21(8-9):705-18 [16028088.001]
  • [Cites] Cancer. 1976 Apr;37(4):1944-52 [1260697.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jul 1;53(3):533-42 [12062594.001]
  • [Cites] Oral Oncol. 2004 Feb;40(2):139-44 [14693236.001]
  • [Cites] Acta Neuropathol. 1973 Oct 11;26(2):171-7 [4763202.001]
  • (PMID = 20668862.001).
  • [ISSN] 1433-0350
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Immunologic Factors; 0 / Interferon-alpha; 0 / alpha-Defensins
  •  go-up   go-down


15. Hargrave DR: Does chemotherapy have a role in the management of craniopharyngioma? J Pediatr Endocrinol Metab; 2006 Apr;19 Suppl 1:407-12
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does chemotherapy have a role in the management of craniopharyngioma?
  • Craniopharyngiomas are classified as histologically benign tumours that are usually treated by surgery alone or in combination with radiotherapy.
  • However, the difficulty in managing recurrent tumours and the desire to try to avoid treatment-related morbidity from both surgery and irradiation has led to exploration of the role of chemotherapy in this tumour.
  • In the majority of cases this has involved the application of intratumoral bleomycin in cystic craniopharyngiomas.
  • This review reports the published experience of this type of local chemotherapy, including delivery, scheduling, outcomes and toxicity.
  • In addition, the rarely reported use of systemic chemotherapy is discussed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Craniopharyngioma / drug therapy. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Antibiotics, Antineoplastic / administration & dosage. Antibiotics, Antineoplastic / adverse effects. Antibiotics, Antineoplastic / therapeutic use. Bleomycin / administration & dosage. Bleomycin / adverse effects. Bleomycin / therapeutic use. Child. Drug Delivery Systems. Humans. Injections

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700318.001).
  • [ISSN] 0334-018X
  • [Journal-full-title] Journal of pediatric endocrinology & metabolism : JPEM
  • [ISO-abbreviation] J. Pediatr. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin
  • [Number-of-references] 29
  •  go-up   go-down


16. Moschovi M, Alexiou GA, Dastamani A, Stefanaki K, Prodromou N, Hatzigiorgi H, Karamolegou K, Tzortzatou-Stathopoulou F: Alpha-fetoprotein secretion in a craniopharyngioma. Are craniopharyngiomas part of the germ cell tumor family? Acta Neurol Belg; 2010 Sep;110(3):272-5
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-fetoprotein secretion in a craniopharyngioma. Are craniopharyngiomas part of the germ cell tumor family?
  • Therefore, systemic chemotherapy was started.
  • Subtotal tumor excision was performed that revealed the presence of a craniopharyngioma.
  • The child received again systemic chemotherapy and placement of a reservoir into the cystic part of the tumor.
  • These observations support the theory of a germ cell tumor family, in which craniopharyngioma and germ cell tumor present the two sides of the same entity, while between them a wide variety of tumors, with variable type of secretion of AFP and/or beta-HCG, may exist.
  • [MeSH-major] Craniopharyngioma. Neoplasms, Germ Cell and Embryonal / classification. Pituitary Neoplasms. alpha-Fetoproteins / secretion
  • [MeSH-minor] Female. Humans. Infant. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21114138.001).
  • [ISSN] 0300-9009
  • [Journal-full-title] Acta neurologica Belgica
  • [ISO-abbreviation] Acta Neurol Belg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  • [Chemical-registry-number] 0 / AFP protein, human; 0 / alpha-Fetoproteins
  •  go-up   go-down


17. Takahashi H, Yamaguchi F, Teramoto A: Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children. Childs Nerv Syst; 2005 Aug;21(8-9):701-4
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term outcome and reconsideration of intracystic chemotherapy with bleomycin for craniopharyngioma in children.
  • OBJECT: We first reported postoperative intratumoral chemotherapy with bleomycin for craniopharyngiomas in 1985.
  • However, this local bleomycin chemotherapy has not yet been used very frequently.
  • It seems to be necessary for us to report long-term outcome and reconsideration of this treatment.
  • METHODS AND RESULTS: Local bleomycin chemotherapy was performed on 7 children (to 1985) and 11 children (from 1988 to 2004).
  • A total of 11 pediatric patients with recurrent cystic craniopharyngioma was treated by intracystic injection of bleomycin after 1988 and followed up from 3 to 16 years.
  • CONCLUSION: Our results indicate that local bleomycin chemotherapy is effective and that recurrence does not occur after follow-up, which ranged in duration from 3 to 16 years.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Craniopharyngioma / drug therapy. Cysts / drug therapy. Drug Therapy / methods. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Retrospective Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Medicines and Children.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiother Oncol. 1993 Apr;27(1):13-21 [8327728.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):120-7 [2578064.001]
  • [Cites] J Antibiot (Tokyo). 1966 Sep;19(5):200-9 [5953301.001]
  • [Cites] J Neurosurg. 1990 Oct;73(4):534-40 [2398383.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Sep 30;27(2):189-95 [8407391.001]
  • [Cites] J Neurosurg Sci. 1989 Jan-Mar;33(1):145-8 [2476533.001]
  • [Cites] Childs Nerv Syst. 2001 Dec;17 (12 ):724-30 [11862438.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1989 Dec;17(6):1313-21 [2689398.001]
  • [Cites] No Shinkei Geka. 1974 Oct;2(10 ):683-8 [4140477.001]
  • [Cites] Acta Neurochir (Wien). 1998;140(5):447-54 [9728244.001]
  • (PMID = 15928963.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


18. Greenberg SB, Magram G: Magnetic resonance cystography with gadopenetate dimeglumine of a cystic craniopharyngioma in a child - a technical note. Pediatr Radiol; 2000 Feb;30(2):85-6
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance cystography with gadopenetate dimeglumine of a cystic craniopharyngioma in a child - a technical note.
  • Large cystic craniopharyngiomas can be treated with chemotherapy injected directly into the cyst.
  • Chemotherapy is toxic if it leaks from the cyst into the subarachnoid space.
  • We present a child with a cystic craniopharyngioma following surgical placement of a catheter into the cystic component.
  • Computed tomography following iodinated contrast injection into the cyst was inconclusive in determining the cyst wall integrity.
  • [MeSH-major] Craniopharyngioma / pathology. Gadolinium DTPA. Magnetic Resonance Imaging. Pituitary Neoplasms / pathology
  • [MeSH-minor] Child, Preschool. Contrast Media. Extravasation of Diagnostic and Therapeutic Materials. Female. Humans. Iohexol

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10663517.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Contrast Media; 4419T9MX03 / Iohexol; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


19. Cavalheiro S, Dastoli PA, Silva NS, Toledo S, Lederman H, da Silva MC: Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma. Childs Nerv Syst; 2005 Aug;21(8-9):719-24
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of interferon alpha in intratumoral chemotherapy for cystic craniopharyngioma.
  • OBJECTIVES: This study analyzed the intratumoral activity of interferon alpha (IFN-alpha) in the treatment of cystic craniopharyngiomas.
  • PATIENTS AND METHODS: From January 2000 to January 2004, nine patients presenting with cystic craniopharyngiomas were treated with intratumoral injection of IFN-alpha at the Pediatric Oncology Institute of the Federal University of São Paulo-Escola Paulista de Medicina.
  • CONCLUSIONS: IFN-alpha proved to be an effective drug in the control of cystic craniopharyngiomas.
  • Additional studies should be carried out to determine the optimal dose of IFN-alpha in the treatment of cystic craniopharyngioma.
  • In addition, other drugs possessing high efficacy and low neurotoxicity should be analyzed.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Craniopharyngioma / drug therapy. Cysts / drug therapy. Interferon-alpha / therapeutic use. Pituitary Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Magnetic Resonance Imaging / methods. Male. Radiography / methods. Retrospective Studies. Tomography, X-Ray Computed / methods. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1985 Jan;62(1):120-7 [2578064.001]
  • [Cites] Blood. 1997 Feb 1;89(3):957-64 [9028327.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:108-13 [7841068.001]
  • [Cites] Apoptosis. 2003 Jun;8(3):237-49 [12766484.001]
  • [Cites] J Neurosurg. 2000 Feb;92 (2):255-60 [10659012.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jan;54(1):1-10 [15693134.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):213-6; discussion 216-7 [10626953.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:64-8 [7841080.001]
  • [Cites] J Neurosurg. 1996 Jan;84(1):124-6 [8613819.001]
  • [Cites] Pediatr Neurosurg. 1994;21 Suppl 1:57-63 [7841079.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1198-205 [8108387.001]
  • [Cites] Cancer. 2002 May 15;94(10 ):2675-80 [12173336.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2269-76 [11489801.001]
  • (PMID = 16133276.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha
  •  go-up   go-down


20. Raco A, Raimondi AJ, D'Alonzo A, Esposito V, Valentino V: Radiosurgery in the management of pediatric brain tumors. Childs Nerv Syst; 2000 May;16(5):287-95
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Seventy-nine patients had multivariate/combined treatment consisting of surgery or biopsy followed by chemotherapy, radiotherapy and/or radiosurgery.
  • Thirty-five were not operated on or biopsied but were treated primarily by radiosurgery, which was associated with chemotherapy and conventional radiotherapy.
  • The short- and long-term results were evaluated separately for each pathology in an attempt to derive guidelines for future treatment.
  • For tumors of the pineal region, we are of the opinion that radiosurgery is the treatment of choice in children and that more than one-third of patients can be cured by this means.
  • The remaining patients require surgery and/or chemotherapy in addition.
  • For medulloblastomas radiosurgery may be useful to control local recurrence if coupled with chemotherapy.
  • We fear that limiting treatment to radiosurgery, rather than prescribing conventional radiotherapy when indicated, could permit CNS seeding.
  • For craniopharyngiomas radiosurgery proved useful for controlling solid remnants.
  • In glial tumors radiosurgery helped either to "sterilize" the tumor bed after removal or to treat remnants of the lesions in critical areas; for diffuse brain stem gliomas it should be considered the treatment of choice.
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Karnofsky Performance Status. Male. Neoplasm Recurrence, Local. Neoplasm Seeding. Neoplasm, Residual / surgery. Prognosis. Radiotherapy. Reoperation. Retrospective Studies. Survival Analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10883372.001).
  • [ISSN] 0256-7040
  • [Journal-full-title] Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
  • [ISO-abbreviation] Childs Nerv Syst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] GERMANY
  •  go-up   go-down


21. Tzotzas T, Papazisis K, Perros P, Krassas GE: Use of somatostatin analogues in obesity. Drugs; 2008;68(14):1963-73
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Insulin, a component of the efferent pathway of the energy-regulatory circuit, promotes storage of energy substrates in adipose tissue and is, therefore, a potential target for pharmacotherapy.
  • These children have hypothalamic dysfunction, mainly due to brain tumours such as craniopharyngiomas, which are thought to generate increased vagal output, leading to hyperinsulinaemia and weight gain.
  • Insulin suppression was associated with small decreases in the body mass indexes of obese subjects receiving the higher dosages of the drug, with an acceptable safety profile, similar to that in previous studies.
  • [MeSH-major] Anti-Obesity Agents / therapeutic use. Hormone Antagonists / therapeutic use. Obesity / drug therapy. Somatostatin / analogs & derivatives. Somatostatin / therapeutic use
  • [MeSH-minor] Adult. Child. Humans. Hypothalamic Diseases / complications. Prader-Willi Syndrome

  • Genetic Alliance. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity.
  • MedlinePlus Health Information. consumer health - Obesity in Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Drugs. 1997 Apr;53(4):681-99 [9098666.001]
  • [Cites] Recent Prog Horm Res. 1998;53:95-117; discussion 117-8 [9769705.001]
  • [Cites] Metabolism. 1992 Sep;41(9 Suppl 2):76-9 [1518438.001]
  • [Cites] Pediatr Endocrinol Rev. 2004 Aug;1 Suppl 3:448-54 [16444173.001]
  • [Cites] Science. 2005 Mar 25;307(5717):1909-14 [15790843.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1811-8 [16507637.001]
  • [Cites] Nutr Rev. 1998 Apr;56(4 Pt 1):106-14 [9584495.001]
  • [Cites] Clin Endocrinol (Oxf). 2002 Oct;57(4):539-46 [12354137.001]
  • [Cites] N Engl J Med. 1996 Jan 25;334(4):246-54 [8532003.001]
  • [Cites] Horm Metab Res. 2006 Jul;38(7):442-6 [16933179.001]
  • [Cites] Horm Res. 1998;49(1):17-21 [9438780.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 May;58(5):653-61 [12699450.001]
  • [Cites] Eur J Endocrinol. 1994 Jun;130(6):581-6 [8205258.001]
  • [Cites] Curr Med Chem. 2001 Nov;8(13):1605-48 [11562281.001]
  • [Cites] Obes Surg. 1993 May;3(2):197-200 [10757921.001]
  • [Cites] Obes Res. 1995 Nov;3 Suppl 4:591S-603S [8697062.001]
  • [Cites] Obes Res. 2005 Sep;13(9):1572-9 [16222060.001]
  • [Cites] Medicine (Baltimore). 1975 Jul;54(4):301-30 [1152672.001]
  • [Cites] Expert Opin Investig Drugs. 2006 Aug;15(8):897-915 [16859393.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Aug;27(8):875-88 [12861227.001]
  • [Cites] Fertil Steril. 2006 Jul;86 Suppl 1:S28-9 [16798283.001]
  • [Cites] J Clin Endocrinol Metab. 2005 May;90(5):2681-90 [15687345.001]
  • [Cites] Int J Obes (Lond). 2006 Feb;30(2):313-21 [16276365.001]
  • [Cites] J Comp Physiol Psychol. 1981 Apr;95(2):278-87 [6112246.001]
  • [Cites] Obesity (Silver Spring). 2006 Jun;14 (6):1028-37 [16861608.001]
  • [Cites] Lancet. 1983 Jun 11;1(8337):1330-1 [6134114.001]
  • [Cites] Diabetes. 1997 Jun;46(6):1025-9 [9166675.001]
  • [Cites] Proc Soc Exp Biol Med. 1988 Dec;189(3):362-6 [2905062.001]
  • [Cites] Neurosci Biobehav Rev. 1982 Summer;6(2):205-14 [7048155.001]
  • [Cites] Intern Med. 1997 May;36(5):319-20 [9213165.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4330-8 [11549670.001]
  • [Cites] Int J Obes Relat Metab Disord. 2004 Feb;28(2):330-3 [14708034.001]
  • [Cites] J Pediatr. 2006 Jan;148(1):23-9 [16423593.001]
  • [Cites] Gut. 2003 Nov;52(11):1555-61 [14570722.001]
  • [Cites] Front Neuroendocrinol. 2003 Jan;24(1):1-10 [12609497.001]
  • [Cites] Nat Med. 2002 Jul;8(7):643-4 [12091883.001]
  • [Cites] Acta Endocrinol Suppl (Copenh). 1987;286:19-25 [2892334.001]
  • [Cites] Obes Rev. 2002 Feb;3(1):27-34 [12119657.001]
  • [Cites] C R Biol. 2006 Aug;329(8):608-22; discussion 653-5 [16860279.001]
  • [Cites] Life Sci. 1979 Aug 13;25(7):561-6 [388132.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Jul;90(7):3854-62 [15827099.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Nov;89(11):5435-40 [15531494.001]
  • [Cites] Endocrinology. 2000 Jan;141(1):111-7 [10614629.001]
  • [Cites] Curr Med Chem. 2004 Jun;11(12):1595-615 [15180566.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Feb;19(2):121-7 [16562584.001]
  • [Cites] Diabetes. 1994 May;43(5):696-702 [8168647.001]
  • [Cites] J Clin Endocrinol Metab. 1977 Jun;44(6):1038-53 [874043.001]
  • [Cites] Clin Chim Acta. 2007 Jan;375(1-2):20-35 [16956601.001]
  • [Cites] J Pediatr. 1999 Aug;135(2 Pt 1):162-8 [10431109.001]
  • [Cites] Mol Endocrinol. 2003 Jan;17(1):93-106 [12511609.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Jun;88(6):2586-92 [12788859.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Nov;92(11):4101-6 [17726084.001]
  • [Cites] Nutr Metab Cardiovasc Dis. 2008 Feb;18(2):158-68 [18061414.001]
  • [Cites] J Clin Endocrinol Metab. 2003 May;88(5):2180-4 [12727973.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Aug;89(8):4162-5 [15292365.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2002 Jun;16(3):493-509 [12079271.001]
  • [Cites] Prog Brain Res. 2006;153:57-73 [16876568.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Aug;88(8):3573-6 [12915638.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Endocr Rev. 1995 Aug;16(4):427-42 [8521788.001]
  • [Cites] J Pediatr. 2005 Apr;146(4):474-81 [15812449.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3298-305 [15240606.001]
  • [Cites] J Clin Endocrinol Metab. 1984 Mar;58(3):544-8 [6363441.001]
  • [Cites] Clin Ophthalmol. 2007 Sep;1(3):209-15 [19668474.001]
  • [Cites] Int J Obes (Lond). 2006 Feb;30(2):331-41 [16158082.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Oct;59(4):492-9 [14510913.001]
  • [Cites] Science. 1973 Jan 5;179(4068):77-9 [4682131.001]
  • [Cites] Trends Genet. 1998 May;14 (5):194-200 [9613204.001]
  • [Cites] Int J Obes Relat Metab Disord. 1993 Sep;17(9):527-32 [8220655.001]
  • [Cites] Diabetologia. 1985 Feb;28(2):70-5 [3884419.001]
  • [Cites] Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Oct;13(3):409-18 [10909432.001]
  • [Cites] Int J Obes Relat Metab Disord. 2003 Feb;27(2):219-26 [12587002.001]
  • [Cites] Pharmacol Biochem Behav. 1982 Jun;16(6):897-902 [6125953.001]
  • [Cites] J Med Chem. 2003 Jun 5;46(12):2334-44 [12773038.001]
  • [Cites] Int J Obes (Lond). 2006 Feb;30(2):382-7 [16231029.001]
  • [Cites] Eur J Endocrinol. 2005 Jun;152(6):887-94 [15941929.001]
  • [Cites] J Endocrinol Invest. 1997 Jun;20(6):348-67 [9294784.001]
  • [Cites] Arch Intern Med. 1991 Aug;151(8):1573-8 [1872661.001]
  • [Cites] J Biol Chem. 1991 Jan 15;266(2):837-43 [1702440.001]
  • (PMID = 18778119.001).
  • [ISSN] 0012-6667
  • [Journal-full-title] Drugs
  • [ISO-abbreviation] Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] New Zealand
  • [Chemical-registry-number] 0 / Anti-Obesity Agents; 0 / Hormone Antagonists; 51110-01-1 / Somatostatin
  • [Number-of-references] 83
  •  go-up   go-down


22. Linnert M, Gehl J: Bleomycin treatment of brain tumors: an evaluation. Anticancer Drugs; 2009 Mar;20(3):157-64
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bleomycin treatment of brain tumors: an evaluation.
  • Bleomycin has been used in the treatment of brain tumors for over 30 years.
  • Twenty-five articles were used for this study based on relevance determined by: (i) clinical studies, (ii) use of bleomycin, and (iii) direct injection into brain tissue or cysts.
  • There were two main indications for the use of bleomycin directly into the brain: (i) cystic tumors in the form of craniopharyngiomas and (ii) solid brain tumors such as glioblastomas and astrocytomas.
  • One death was directly related to this treatment, where very high doses were used.
  • Two patients developed loss of vision and two patients had hearing loss because of the treatment.
  • All cases with severe and moderate adverse effects except one were patients with craniopharyngiomas and probably because of tumor localization in the deep brain.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Brain Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Blindness / chemically induced. Brain Edema / chemically induced. Child. Child, Preschool. Craniopharyngioma / drug therapy. DNA Damage. Deafness / chemically induced. Electroporation. Female. Glioma / drug therapy. Humans. Infant. Injections, Spinal. Male. Middle Aged. Pituitary Neoplasms / drug therapy. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19396014.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 11056-06-7 / Bleomycin
  • [Number-of-references] 43
  •  go-up   go-down


23. Bouffet E: Common brain tumours in children: diagnosis and treatment. Paediatr Drugs; 2000 Jan-Feb;2(1):57-66
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common brain tumours in children: diagnosis and treatment.
  • The role of chemotherapy remains ill-defined in many patients with brain tumours and large variations in practice exist between groups and institutions.
  • This article provides an overview of the most common paediatric brain tumours, mainly gliomas, medulloblastomas, ependymomas, germ-cell tumours and craniopharyngiomas.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Brain Neoplasms / therapy
  • [MeSH-minor] Child. Genetic Therapy. Humans. Immunotherapy

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Optom Clin. 1993;3(3):127-34 [8199445.001]
  • [Cites] J Neurooncol. 1998 May;37(3):229-39 [9524081.001]
  • [Cites] J Neurosurg. 1998 Jul;89(1):52-9 [9647172.001]
  • [Cites] J Neurosurg. 1997 May;86(5):747-54 [9126887.001]
  • [Cites] Cancer. 1997 Nov 1;80(9):1792-7 [9351549.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1199-204 [10098759.001]
  • [Cites] J Neurosurg. 1990 Apr;72(4):572-82 [2319316.001]
  • [Cites] Neurology. 1994 Oct;44(10):1798-803 [7936224.001]
  • [Cites] Med Pediatr Oncol. 1996 Jul;27(1):8-14 [8614396.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Nov 15;30(4):781-7 [7960979.001]
  • [Cites] Eur J Cancer. 1990 Apr;26(4):464-9 [2141512.001]
  • [Cites] Med Pediatr Oncol. 1998 Jun;30(6):319-29; discussion 329-31 [9589080.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):233-44 [8832465.001]
  • [Cites] J Neurosurg. 1987 Feb;66(2):227-33 [3806204.001]
  • [Cites] J Clin Oncol. 1987 Aug;5(8):1221-31 [3040919.001]
  • [Cites] J Neurooncol. 1996 Jul;29(1):45-54 [8817415.001]
  • [Cites] Med Pediatr Oncol. 1995 Sep;25(3):166-78 [7623725.001]
  • [Cites] Radiother Oncol. 1993 Jan;26(1):1-10 [8438080.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):167-176; discussion 176-7 [8873158.001]
  • [Cites] J Neurosurg. 1996 Jul;85(1):73-81 [8683285.001]
  • [Cites] Med Pediatr Oncol. 1987;15(5):241-53 [3309606.001]
  • [Cites] J Child Neurol. 1993 Oct;8(4):287-91 [8228023.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):874-80 [8756384.001]
  • [Cites] J Neurooncol. 1989 Jul;7(2):165-77 [2550594.001]
  • [Cites] Nat Med. 1997 Dec;3(12):1354-61 [9396605.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):238-42 [3944633.001]
  • [Cites] J Neurosurg. 1995 Apr;82(4):536-47 [7897512.001]
  • [Cites] Cancer. 1993 May 15;71(10 Suppl):3229-36 [8490859.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1458-65 [8336185.001]
  • [Cites] Klin Padiatr. 1993 Jul-Aug;205(4):217-24 [7690863.001]
  • [Cites] Cancer. 1994 Sep 15;74(6):1827-34 [8082086.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):45-60; discussion 60-1 [8121569.001]
  • [Cites] J Neurosurg. 1997 May;86(5):755-61 [9126888.001]
  • [Cites] J Clin Oncol. 1996 Sep;14(9):2495-503 [8823328.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):905-9 [2033450.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):112-23 [7799011.001]
  • [Cites] Radiother Oncol. 1992 Jun;24(2):77-81 [1323134.001]
  • [Cites] Neurosurgery. 1995 Nov;37(5):894-8 [8559337.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):157-66 [8832459.001]
  • [Cites] Bull Cancer. 1990;77(7):699-713 [2207360.001]
  • [Cites] Am J Clin Oncol. 1994 Dec;17(6):475-9 [7977163.001]
  • [Cites] Pediatr Neurosurg. 1995;22(4):189-96 [7619719.001]
  • [Cites] J Neurooncol. 1997 May;32(3):235-41 [9049885.001]
  • [Cites] Cancer. 1991 Jun 1;67(11):2766-71 [2025840.001]
  • [Cites] Anesthesiology. 1982 Oct;57(4):338-9 [7125277.001]
  • [Cites] J Neurooncol. 1993 Feb;15(2):133-9 [8509818.001]
  • [Cites] Cancer. 1997 Aug 1;80(3):497-504 [9241084.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):899-904 [8598368.001]
  • [Cites] Eur J Cancer. 1992;28(2-3):511-3 [1591076.001]
  • [Cites] J Neurooncol. 1996 May-Jun;28(2-3):223-31 [8832464.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Aug;21(3):825-30 [1831193.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):222-8 [9440746.001]
  • [Cites] J Clin Oncol. 1996 Nov;14(11):2908-15 [8918487.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1725-31 [8388548.001]
  • [Cites] J Neurosurg. 1994 Nov;81(5):690-8 [7931615.001]
  • [Cites] Arch Dis Child. 1997 Jan;76(1):76-8 [9059170.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1607-15 [8040673.001]
  • [Cites] Pediatr Neurosurg. 1996 Oct;25(4):182-7 [9293545.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]
  • [Cites] Neurosurgery. 1991 May;28(5):666-71; discussion 671-2 [1876244.001]
  • [Cites] Pediatr Neurosurg. 1993;19(1):6-14 [8422329.001]
  • [Cites] Med Pediatr Oncol. 1994;23(5):422-7 [8084309.001]
  • [Cites] Pediatr Neurosurg. 1996 Jul;25(1):7-12 [9055328.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2391-9 [9840540.001]
  • [Cites] Neurosurgery. 1996 Feb;38(2):258-64 [8869052.001]
  • [Cites] Med Pediatr Oncol. 1992;20(3):181-91 [1574027.001]
  • [Cites] J Clin Oncol. 1991 May;9(5):783-8 [2016620.001]
  • [Cites] J Neurosurg. 1993 Dec;79(6):845-52 [8246052.001]
  • [Cites] Neurosurgery. 1995 Oct;37(4):655-66; discussion 666-7 [8559293.001]
  • [Cites] J Neurooncol. 1996 Jan;27(1):87-98 [8699230.001]
  • [Cites] Cancer. 1997 Jul 15;80(2):341-7 [9217048.001]
  • [Cites] Eur J Cancer. 1997 Jan;33(1):91-5 [9071906.001]
  • [Cites] Pediatr Neurosurg. 1996;24(4):185-92 [8873160.001]
  • [Cites] Neurosurgery. 1997 Apr;40(4):856-60; discussion 860 [9092863.001]
  • (PMID = 10937458.001).
  • [ISSN] 1174-5878
  • [Journal-full-title] Paediatric drugs
  • [ISO-abbreviation] Paediatr Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 66
  •  go-up   go-down


24. Kim SD, Park JY, Park J, Lee JB, Kim SH, Lim DJ: Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma. Clin Neurol Neurosurg; 2007 Apr;109(3):236-41
Hazardous Substances Data Bank. BLEOMYCIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiological findings following postsurgical intratumoral bleomycin injection for cystic craniopharyngioma.
  • OBJECTIVES: The purpose of this study was to compare the radiological findings before and after intratumoral bleomycin injection in patients with cystic craniopharyngioma so as to define the role of adjuvant intracavitary bleomycin chemotherapy for cystic craniopharyngiomas.
  • PATIENTS AND METHODS: Eleven patients whose craniopharyngioma was confirmed cytologically and/or histologically were retrospectively reviewed.
  • Only the solid portion of the cystic craniopharyngiomas was excised before repeated injections of bleomycin (15-180 mg in total) into the cystic portion through an Ommaya reservoir were given.
  • RESULTS: After the completion of all treatment cycles, the disappearance or shrinkage of the tumor was initially noted in all cases on follow-up CT and/or MR imaging studies.
  • However, tumor recurrence was seen in four cases with a mixed tumor type.
  • CONCLUSION: Postoperative bleomycin injection in cystic craniopharyngioma does not appear to totally eradicate the tumor and does not stop tumor recurrence unless the cyst is the only portion of the craniopharyngioma that is left.
  • Nevertheless, postoperative bleomycin injection decreases and stabilizes tumor size, and thus may be considered as an option of treatment modalities in patients with predominantly cystic craniopharyngiomas.
  • [MeSH-major] Antibiotics, Antineoplastic / therapeutic use. Bleomycin / therapeutic use. Craniopharyngioma. Cysts. Magnetic Resonance Imaging. Pituitary Neoplasms. Tomography, X-Ray Computed
  • [MeSH-minor] Adolescent. Adult. Aged. Brain / pathology. Brain / radiography. Brain / surgery. Child. Combined Modality Therapy. Female. Humans. Injections. Male. Middle Aged. Neurosurgical Procedures. Postoperative Care

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17046151.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 11056-06-7 / Bleomycin
  •  go-up   go-down


25. Pancucci G, Massimi L, Caldarelli M, D'Angelo L, Sturiale C, Tamburrini G, Tufo T, Di Rocco C: [Pediatric craniopharyngioma: long-term results in 61 cases]. Minerva Pediatr; 2007 Jun;59(3):219-31
MedlinePlus Health Information. consumer health - Pituitary Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pediatric craniopharyngioma: long-term results in 61 cases].
  • [Transliterated title] Craniofaringioma pediatrico: risultati a lungo termine in 61 casi.
  • AIM: The aim of this study was to analyze the long-term results of the surgical management of craniopharyngioma in children by reviewing a series of patients consecutively treated in a single institution, and to assess the efficacy of intratumoral chemotherapy with interferon-alpha.
  • Interferon-a was useful in transitorily arresting the growing cystic craniopharyngiomas.
  • CONCLUSION: The current experience confirms the still remarkable challenges in the treatment of craniopharyngioma in childhood.
  • Intracystic chemotherapy with interferon-alpha might represent an effective option to postpone the surgical operation until the maturation of the hypothalamic-hypophyseal pathway is completed.
  • [MeSH-major] Brain / pathology. Craniopharyngioma / therapy. Hypophysectomy. Pituitary Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Injections, Intralesional. Interferon-alpha / therapeutic use. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Recombinant Proteins. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17519867.001).
  • [ISSN] 0026-4946
  • [Journal-full-title] Minerva pediatrica
  • [ISO-abbreviation] Minerva Pediatr.
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a
  •  go-up   go-down


26. Darendeliler F, Karagiannis G, Wilton P, Ranke MB, Albertsson-Wikland K, Anthony Price D, On Behalf Of The Kigs International Board: Recurrence of brain tumours in patients treated with growth hormone: analysis of KIGS (Pfizer International Growth Database). Acta Paediatr; 2006 Oct;95(10):1284-90
MedlinePlus Health Information. consumer health - Childhood Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Growth hormone (GH) has been used successfully in the treatment of short stature secondary to GH deficiency in survivors of childhood brain tumours.
  • METHODS: Data for tumour recurrence were analysed retrospectively in 1038 patients with craniopharyngiomas, 655 with medulloblastomas, 113 with ependymomas, 297 with germinomas, and 400 with astrocytomas or gliomas.
  • RESULTS: Recurrence-free survival rates were 63% at a follow-up of 10.3 y in craniopharyngioma, 69% in 9.1 y in the glial tumours, 71% in 7.4 y in germinomas, 92% in 4.6 y in medulloblastomas and 89% in 2.5 y in ependymomas.
  • Dose of GH and treatment modalities did not differ significantly between patients with and without recurrence.
  • CONCLUSION: Tumour recurrence rates in surviving patients with brain tumours receiving GH treatment do not appear to be increased compared with published reports.
  • [MeSH-major] Brain Neoplasms / drug therapy. Human Growth Hormone / therapeutic use. Neoplasm Recurrence, Local / epidemiology. Recombinant Proteins / therapeutic use
  • [MeSH-minor] Adolescent. Astrocytoma / drug therapy. Astrocytoma / mortality. Astrocytoma / radiotherapy. Astrocytoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Craniopharyngioma / drug therapy. Craniopharyngioma / mortality. Craniopharyngioma / radiotherapy. Craniopharyngioma / surgery. Disease-Free Survival. Ependymoma / drug therapy. Ependymoma / mortality. Ependymoma / radiotherapy. Ependymoma / surgery. Female. Germinoma / drug therapy. Germinoma / mortality. Germinoma / radiotherapy. Germinoma / surgery. Humans. Male. Medulloblastoma / drug therapy. Medulloblastoma / mortality. Medulloblastoma / radiotherapy. Medulloblastoma / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982503.001).
  • [ISSN] 0803-5253
  • [Journal-full-title] Acta paediatrica (Oslo, Norway : 1992)
  • [ISO-abbreviation] Acta Paediatr.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Recombinant Proteins; 12629-01-5 / Human Growth Hormone
  •  go-up   go-down






Advertisement